MedicNova receives notice of allowance for new patent covering MN-001, MN-002 MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of nonalcoholic fatty liver disease. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032. The allowed claims cover a method of treating nonalcoholic fatty liver disease and a method of reducing liver inflammation in nonalcoholic fatty liver disease using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.
MediciNova granted orphan status for idiopathic pulmonary fibrosis drug The FDA posted on its website that MediciNova has been granted orphan status for its treatment of idiopathic pulmonary fibrosis. Reference Link